



Combined Treatments and Therapies to Cure Spinal Cord Injury

Guest Editor:

Dr. Nicolas Guerout

SPPIN - Saints-Pères Paris
Institute for the Neurosciences -
CNRS UMR 8003, Université Paris
Cité, F-75006 Paris, France

Deadline for manuscript
submissions:

closed (15 November 2023)

Message from the Guest Editor

Spinal cord injury (SCI) is a rare disease of the central nervous system (CNS), most often originating from trauma following road accidents, falls or violence, causing the loss of motor, sensory and autonomic functions. To date, there is no curative treatment that can be offered to injured patients. Many treatments have been tested to allow tissue and functional recovery after SCI. However, the complexity of the injury suggests that a single treatment is not sufficient to induce real benefits in humans. Therefore, it is thought that only the use of combination therapies would be effective in promoting recovery after SCI, although the ideal combination remains to be determined.

We cordially invite you to contribute to this Special Issue. Our aim is to provide most relevant information concerning innovative treatment modalities and their combinations as potential innovative treatments after SCI. Original investigations and review articles are both welcome.

- spinal cord injury
- tissue repair
- functional recovery
- combined treatments
- innovative therapy
- glial scar
- inflammation
- axonal regrowth





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)